Skip to content
naulon
Not checkedNot checked for notices yet.

The Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease

Daniele Caligiore, Flora Giocondo, Massimo Silvetti

IBRO Neuroscience Reports · 2022

doi:10.1016/j.ibneur.2022.09.007 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Increasing evidence suggests that Alzheimer’s disease (AD) and Parkinson’s disease (PD) share monoamine and alpha-synuclein (αSyn) dysfunctions, often beginning years before clinical manifestations onset. The triggers for these impairments and the causes leading these early neurodegenerative processes to become AD or PD remain unclear. We address these issues by proposing a radically new perspective to frame AD and PD: they are different manifestations of one only disease we call “Neurodegenerative Elderly Syndrome (NES)”. NES goes through three phases. The seeding stage, which starts years before clinical signs, and where the part of the brain-body affected by the initial αSyn and monoamine dysfunctions, influences the future possible progression of NES towards PD or AD. The compensatory stage, where the clinical symptoms are still silent thanks to compensatory mechanisms keeping monoamine concentrations homeostasis. The bifurcation stage, where NES becomes AD or PD. We present recent literature supporting NES and discuss how this hypothesis could radically change the comprehension of AD and PD comorbidities and the design of novel system-level diagnostic and therapeutic actions.

Abstract licence: CC BY-NC-ND

References286

  1. 13.

39 more references, whose wording the paper’s licence keeps private.

All 286 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.